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Gingival fibroblast cell lines were derived from Sorsby’s fundus dystrophy (SFD) patients carrying the S181C TIMP3 and the E139X
TIMP3 mutations. These cell lines were grown in culture to study expression of the wild-type and mutant tissue inhibitor of metalloproteinase
3 (TIMP3) alleles from a normal diploid cell type. Firstly, patient cells were found to co-express the wild-type and mutant TIMP3 alleles,
S181C TIMP3 or E139X TIMP3, at the mRNA level using restriction fragment length polymorphism (RFLP) analysis. A SpeI RFLP for
E139X TIMP3 is described. Low levels of endogenous TIMP3 protein expression were elevated using the natural polysaccharide calcium
pentosan polysulfate (CaPPs) in combination with the cytokine IL-1a. Immunoblotting detected protein expression from both wild-type and
mutant alleles, S181C TIMP3 or E139X TIMP3. S181C TIMP3 from these cells was found to dimerise and retain MMP2 inhibitory activity.
To facilitate studies of the E139X TIMP3 protein, the allele was expressed using HighFive insect cells. In this cell type, the E139X TIMP3
was synthesised as a mixture of monomer and dimer. Both monomeric and dimeric E139X TIMP3 protein retained MMP2 inhibitory activity
in gelatin zymography. Expression of mutant E139X or S181C TIMP3 protein from a normal diploid patient-derived fibroblast cell had no
effect on either MMP2 or MMP9 expression or activation whilst transcribed from their normal promoter context.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Retinal pigment epithelium; Sorsby’s fundus dystrophy; TIMP3; CaPPs; IL-1a; Metalloproteinase; Extracellular matrix1. Introduction
Sorsby’s fundus dystrophy (SFD) is a rare autosomal
dominant macular dystrophy which manifests as loss of
central vision, usually in the fourth or fifth decades [1].
Central visual loss in SFD is usually due to neovascular0925-4439/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
doi:10.1016/S0925-4439(03)00036-X
Abbreviations: ARMD, age-related macular degeneration; BHK, baby
hamster kidney; BNC, bovine nasal cartilage; CaPPs, calcium pentosan
polysulfate; Con A, concanavalin A; DMEM, Dulbecco’s modified Eagle
medium; ECM, extracellular matrix; FCS, fetal calf serum; HRP,
horseradish peroxidase; RPE, retinal pigment epithelium; RFLP, restriction
fragment length polymorphism; SFD, Sorsby’s fundus dystrophy; TIMP3,
tissue inhibitor of metalloproteinase 3; MMP, matrix metalloproteinase;
TBS, Tris-buffered saline
* Corresponding author. Department of Rheumatology and Gerentol-
ogy, University of Newcastle Medical School, Framlington Place, New-
castle-upon-tyne NE2 4HH, UK. Tel.: +44-191-222-5902; fax: +44-191-
222-5455.
E-mail address: norman.mckie@ncl.ac.uk (N. McKie).(wet type) macular degeneration [2] but can be atrophic (dry)
without neovascularisation [3,4]. SFD also causes peripheral
retinal abnormalities detectable by electroretinography [2]
and manifesting as symptomatic night blindness which usu-
ally precedes central visual loss [5,6]. Defective colour
vision, particularly at the blue end of the spectrum, has also
been described as an early feature [7]. Night blindness and
peripheral visual field loss in SFD is reversible in some cases
by treatment with high dosage vitamin A [8]. Thickening of
Bruch’s membrane in SFD is also observed which stains
strongly for tissue inhibitor of metalloproteinase 3 (TIMP3)
[9,10]. SFD pathogenesis usually involves subretinal neo-
vascularisation secondary to which atrophy of the chorioca-
pillaris, retinal pigment epithelium (RPE) and photoreceptors
occur [3]. These may, however, represent primary changes in
the absence of neovascularisation [3]. Although SFD is a very
rare condition, it has generated a great deal of interest because
its phenotype closely resembles that of the exudative form of
age-related macular degeneration (ARMD), the leading causeed.
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western world [11].
SFD is known to be associated with mutations in TIMP3.
TIMP3 is a member of a family of four secreted proteins
which inhibit the activity of matrix metalloproteinases
(MMPs), a rapidly expanding class of secreted and cell
surface neutral zinc endopeptidases ubiquitously involved in
tissue remodelling. Substrates for MMPs are sufficiently
disparate to include virtually all extracellular matrix (ECM)
molecules, other proteinases, cell surface receptors, cell
adhesion molecules, latent growth factors and growth-factor
binding proteins (see Sternlicht and Werb [12] and Sivak
and Fini [13] for reviews). The balance between TIMPs and
MMPs is one of the mechanisms by which MMP activity is
regulated and places TIMPs at the centre of such diverse
physiological and pathological processes as wound healing,
inflammation, angiogenesis and tumour metastases [12,13].
Mammalian TIMPs 1–4 show marked conservation of
structure. Each TIMP comprises two domains, N- and C-
terminal, consisting of approximately 125 and 65 amino
acids, respectively. The three-lobed structure of each
domain is maintained by three disulfide bonds formed
between a total of 12 conserved cysteines, 6 in each domain.
The N-terminal domain is highly conserved and is sufficient
for MMP inhibition [14,15], whereas the C-terminal domain
is more divergent and appears to be responsible for differ-
ences between the TIMP family members, for example,
possession of different affinities for pro-MMPs [16,17].
TIMP3 is unique amongst the TIMP family members for
several reasons. TIMP3 is alone in having an ECM binding
capacity, which it mediates in large part via its C-terminal
domain [15]. However, the N-terminal of TIMP3 has also
been shown to bind heparin [18]. The range of proteinases
inhibited by TIMP3 includes both ADAM and ADAMts
family members [19–21]. Furthermore, the N-terminal
domain contains a ‘‘pro-death domain’’, the induction of
apoptosis being associated with the presence of a functional
MMP-inhibitory activity [22–24]. TIMP3 mRNA has been
reported to be regulated during cell cycle progression,
differentiation and senescence, implicating a role for
TIMP3 in these processes [24]. It also promotes the detach-
ment of transforming cells from the ECM [25], a property
perhaps relevant to its known effects on cell cycle pro-
gression.
To date, nine point mutations in TIMP3 which give rise
to SFD have been characterised. Seven of these result in
the substitution of a cysteine residue for another amino
acid in exon 5 (S156C [26], G166C [27], G167C [8],
Y168C [28], Y172C [29], S181C [28]). Of the other two
known mutations, one is located at the exon 4/5 splice
boundary and mutates a splice acceptor site [30]. The other
is an exon 5 mutation which introduces a termination
codon E139X [7,31]. The mutations altering exon 5 of
the TIMP3 result in an unpaired cysteine in the C terminus.
The biochemical properties of the SFD-TIMP3 proteins
have been studied using COS-7 expression systems [15,31]and baby hamster kidney cell (BHK) expression systems
[32]. S156C SFD-TIMP3 has also been studied by expres-
sion in the ARPE-19 retinal pigment epithelial cell line
[33]. In the first two studies, S156C, G166C, G167C,
Y168C and S181C TIMP3 proteins were shown to retain
localisation to the ECM and retain MMP inhibitory activity
when expressed in either COS-7 [15,31] or BHK cells
[32]. E139X TIMP3 protein has also been shown to retain
ECM localisation when expressed in COS-7 cells [31]. All
of these SFD-TIMP3 proteins have been demonstrated to
form dimers and other oligomeric forms [15,31,32]. The
S156C SFD-TIMP3-specific report, in contrast to the
above studies, demonstrated that this protein did not
dimerise and showed reduced gelatinase inhibition in
human ARPE-19 cells [33]. Furthermore, expression of
the S156C SFD-TIMP3 protein in this cell type also
resulted in increased secretion and activation of MMP2
and MMP9 [33]. To understand the properties of SFD-
TIMP3 alleles in patients, we undertook a study of the
expression of S181C-TIMP3 and E139X TIMP3 in gin-
gival fibroblasts derived from SFD patients carrying these
mutations.2. Materials and methods
2.1. Cell culture
Gingival explants approximately 5 mm3 were obtained
from one S181C patient (female, age 54 years) and one
E139X patient (female, age 55 years). After extensive
washing in Dulbecco’s modified Eagle medium (DMEM)
(25 mM HEPES) supplemented with 1000 units/ml peni-
cillin and 1000 Ag/ml streptomycin, each explant was
transferred to a six-well plate and finely minced with a
sterile scalpel blade. Two milliliters of DMEM supple-
mented with 10% fetal calf serum (FCS), 500 units/ml
penicillin, 500 Ag/ml streptomycin and 20 units/ml fungi-
zone was added and the plates were incubated at 37 jC in a
5% CO2/95% air atmosphere. Medium was changed regu-
larly until outgrowth of fibroblasts from the gingival frag-
ments covered more than 70% of the well (2–3 weeks).
Fibroblasts were washed with Ca2 + Mg2 +-free phosphate-
buffered saline, stripped with 0.05% trypsin (w/v) and
0.02% EDTA tetrasodium salt and transferred to a T25
flask. Patient gingival fibroblasts were subsequently main-
tained in DMEM (25 mM HEPES) substituted with 10%
FCS, 20 units/ml fungizone, and either 100 Ag/ml kanamy-
cin (E139X TIMP3 fibroblasts) or 100 units/ml penicillin
and 100 Ag/ml streptomycin (S181C TIMP3 fibroblasts).
Cultures were routinely passaged by dissociation with
0.05% trypsin (w/v) and 0.02% EDTA, tetrasodium salt,
followed by replating at a split ratio of 1:3. HighFive
lepidopteran cells (Invitrogen) were maintained at 27 jC
in Ultimate Insect serum-free medium (Invitrogen) supple-
mented with 10 Ag/ml gentamycin (Gibco). For the purposes
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diameter tissue culture dishes.
2.2. Restriction fragment length polymorphism analysis
Total RNA was harvested from patient fibroblasts using
Qiagen’s RNeasy kit according to the manufacturer’s
instructions. Reverse transcription and TIMP3 exon 4/5
amplification was achieved using One-step RT-PCR kit
(Qiagen) according to the manufacturer’s instructions and
1 Ag of RNA per reaction. Primers for amplification of exon
4/5 were designed such that the PCR product spans the exon
4/5 boundary, thereby distinguishing between genomic and
mRNATIMP3 sequences. Primer sequences were T3ex4f 5V
CTGTGCAACTTCGTGGAG 3V and T3ex5R 5VGGG-
TCTGTGGCATTGATG 3V. RT-PCR conditions were 50
jC 30 min reverse transcription, 95 jC 15 min RT inacti-
vation and Taq activation, followed by 30 cycles of 94 jC
for 30 s, 60 jC for 30 s, 72 jC for 60 s, and a final extension
10 min at 72 jC. Restriction fragment length polymorphism
(RFLP) analysis was performed by digesting the PCR
product with SpeI (New England Biolabs), which detects
the E139X mutation and with NsiI (New England Biolabs)
which detects the S181C mutation.
2.3. Preparation of cells/ECM and conditioned medium
Conditioned medium was removed from confluent
monolayers and cleared by centrifugation at 700 g. Con-
ditioned medium was either transferred directly to sample
buffer or stored untreated. Confluent monolayers of cells
were washed in Ca2 + Mg2 +-free phosphate-buffered saline
and the cells and ECM fractions harvested by scraping into
Laemmli sample buffer without reducing agent. All samples
were stored at  80 jC immediately after harvesting.
Protein concentrations were estimated using either the
Pierce BCA assay kit or by visual inspection of Coomassie
G-250 Brilliant Blue-stained polyacrylamide gels.
2.4. CaPPs/IL-1a treatment
When cells reached confluence, they were transferred to
serum-free DMEM (25 mM HEPES) containing 0.2% h-
lactalbumin hydrolysate for 24 h before treatment for 5 days
with 10 Ag/ml calcium pentosan polysulfate (CaPPs; a kind
gift of Professor Peter Ghosh, University of Sydney, Aus-
tralia) and 1 ng/ml IL-1a (a kind gift of Professor T.E.
Cawston, University of Newcastle, United Kingdom) in
serum-free DMEM (25 mM HEPES) containing 0.2% h-
lactalbumin hydrolysate.
2.5. Immunoblotting
Reduced (heated for 5 min at 95 jC with 2.5% 2-
mercaptoethanol) or non-reduced samples were separated
on 15% polyacrylamide gels containing 0.09% SDS andtransferred onto nitrocellulose membrane (Amersham).
Membranes were incubated in blocking buffer (TBS, 0.1%
Tween-20, 5% skimmed milk) for 1–2 h at room temper-
ature then probed with primary antibody (rabbit anti-human
TIMP3 N-terminal first loop polyclonal: Sigma T7687)
diluted 1:5000 in blocking buffer for 16 h at 4 jC.
Membranes were probed with secondary antibody (goat
anti-rabbit–horseradish peroxidase (HRP) conjugate, Dako)
diluted 1:10,000 in blocking buffer for 1 h at room temper-
ature. Membranes were washed in TBS, 0.1% Tween-20 for
a minimum of three 10-min washes after each antibody
incubation. Proteins were visualised using ECL-Plus (Amer-
sham) according to the manufacturer’s instructions.
2.6. Zymograms and reverse zymograms
Equal amounts of protein were loaded on a 7.5% SDS
polyacrylamide gel with 1.25 mg/ml gelatin for zymography
or a 15% SDS polyacrylamide gel with 2.33 mg/ml gelatin
and 0.08 Ag/ml recombinant MMP2 (R&D Systems) as a
source of gelatinase activity for reverse zymography. Fol-
lowing electrophoresis, gels were processed as described
previously [34]. Briefly, gels were agitated in a solution of
2.5% Triton X-100 in 50 mM Tris (pH 7.6), 5 mM CaCl2, 1
AM ZnCl2 to remove SDS and promote renaturation of
proteases. The Triton was washed off with 50 mM Tris (pH
7.8), 150 mM NaCl, 10 mM CaCl2, 0.125% Brij for reverse
zymograms and 0.1 M glycine (pH 7.6) for zymograms, and
the gels then incubated in the same buffer for 16 h at 37 jC.
Gels were stained with 0.25% Coomassie G-250 in acetic
acid/methanol/water (1:5:5) for 2 h and destained in acetic
acid/methanol/water (1:4.5:4.5).
2.7. Expression of E139X TIMP3 protein in HighFive insect
cells
The TIMP3 E139X TIMP3 coding sequence was ampli-
fied from the vector pCDNATIMP-3 [15] using the primers
T IMP3WILDTYPE F 5V CTGGATCCATGAC-
CCCTTGGCTCGG and 3VTIMP3E139X TIMP3 R 5V
CTCTCGAGTTAGTTCTTGGAAGTCACAAAGC 3V. The
PCR programmewas 3min at 95 jC followed by 25 cycles of
1 min 95 jC, 30 s at 55 jC, 1 min at 72 jC, then a final 5-min
extension at 72 jC. The PCR fragment was gel purified using
QIAquick gel extraction kit (Qiagen) according to the man-
ufacturer’s instructions. The fragment was cloned into pIB/
V5-His TOPO vector using the pIB/V5-His TOPOR TA
cloning kit (Invitrogen) according to the manufacturer’s
instructions. Plasmids were isolated using Qiagen Miniprep
kit (Qiagen) according to the manufacturer’s instructions.
Plasmids were analysed for the presence of an insert by
restriction enzyme digest with BamHI and XhoI, and for
orientation by digestion with XhoI. Identity and integrity of
the cloned sequence was confirmed by DNA sequencing.
Plasmid for transfection of HighFive cells was purified using
a Midiprep Kit (Qiagen) according to the manufacturer’s
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(Invitrogen). Stable cell lines were selected on blasticidin,
according to the Insect Select manual (Invitrogen). Expres-
sion of E139X TIMP3 was tested by immunoblotting.
2.8. Concanavalin A treatment
When cells reached confluence, they were transferred to
serum-free DMEM (25 mM HEPES) containing 0.2% h-
lactalbumin hydrolysate for 24 h before treatment with
concentrations of Concanavalin A (Con A) ranging from 0
to 100 Ag/ml in serum-free DMEM (25 mM HEPES)
containing 0.2% h-lactalbumin hydrolysate.
2.9. Partial purification of E139X TIMP3
E139X TIMP3 was partially purified by heparin-affinity
chromatography. Heparin–Sepharose (Pharmacia Biotech)
slurry was prepared according to the manufacturer’s instruc-
tions and equilibrated in 20 mM Tris–Cl, 75 mM NaCl,
0.025% Brij-35, 0.02% sodium azide (pH 6.8). Conditioned
medium harvested from confluent flasks of HighFive cells
expressing the E139X TIMP3 was diluted 1:1 with 40 mM
Tris–Cl, 0.05% Brij-35 and 0.04% sodium azide (pH 6.8),
mixed with prepared slurry and incubated with agitation for
16 h at 4 jC. Post-incubation, the binding mix was applied
to a column and washed with wash buffer (40 mM Tris–Cl;
150 mM NaCl; 0.05% Brij-35, 0.04% sodium azide, pH
6.8). Bound proteins were batch eluted with 1 M NaCl.
Aliquots were stored at  20 jC. Fractions containing
E139X TIMP3 were identified by immunoblotting.Fig. 1. RFLP analysis of TIMP3 expression in SFD patient gingival
fibroblasts. Restriction digests of TIMP3 exon 4/5 amplicon derived from
gingival fibroblasts from a patient carrying the S181C TIMP3 mutation and
a patient carrying the E139X TIMP3 mutation. Lane 1, E139X/NsiI; lane 2,
S181C/NsiI; lane 3, E139X/SpeI; lane 4, S181C/SpeI.3. Results and discussion
3.1. Growth and maintenance of the SFD-TIMP3 fibroblast
cell lines
Gingival fibroblasts carrying either S181C or E139X
TIMP3 mutations were phenotypically normal and grew in
standard tissue culture conditions, requiring the addition of
10% fetal bovine serum but no additional growth factors.
E139X TIMP3 cells grew more vigorously than S181C
TIMP3 cells, senesced at a later passage as manifest by a
100% increase in cell doubling time (p20 compared with
p17) and remained viable for more passages (still cycling at
p27 compared with no longer cycling at p23). Both cell lines
were, however, well within the ranges of longevity in
culture and passage number at which senescence occurred
previously reported for normal fibroblasts in culture [35].
3.2. Expression of the E139X TIMP3 and S181C TIMP3
mRNA in fibroblasts derived from SFD patients
Previous publications from our laboratory and others
have reported on the expression and biochemical character-isation of S156C, G166C, S181C and E139X TIMP3
proteins [15,31–33]. These studies rely on production of
mutant TIMP3 in recombinant systems and it is therefore an
important proof of principle to demonstrate that Sorsby’s
patients do indeed express mutant TIMP3 mRNA and hence
mutant TIMP3 protein. To date, only one study has
addressed this issue where it was reported that dermal
fibroblasts derived from both S156C and S181C SFD
patients express mutant TIMP3 proteins [36]. We have
established primary fibroblast cell lines by explant culture
from gingival biopsies from an independent S181C pedigree
and an E139X pedigree to further address this point.
Initial characterisation of E139X TIMP3 and S181C
TIMP3 gene expression in SFD patient fibroblasts was
performed by RFLP analysis. The S181C TIMP3 mutation
is known to introduce an NsiI site into exon 5 of TIMP3,
which is not present in the wild-type allele, as previously
analysed by Weber et al. [28]. Digestion of the 283-base-
pair exon 4/5 PCR product derived from S181C TIMP3
cells allowed identification of expression of both wild-type
(283 base pair) and S181C TIMP3 (262 plus 21 base pair
fragments, the latter not visible on gel) alleles (Fig. 1, lane
2). Study of the sequence change in exon 5 in TIMP3,
which gives rise to the E139X TIMP3 variant, revealed that
a SpeI restriction site is introduced into the mutant allele
(wild type: ACGAGT, E139X: ACTAGT). Thus, digestion
of the 283-base-pair exon 4/5 PCR product derived from
E139X TIMP3 cells allowed identification of expression of
both wild-type (283 base pair) and E139X TIMP3 (148 plus
135 base pair fragments) alleles (Fig. 1, lane 3). Reciprocal
digests, of E139X TIMP3 with NsiI and S181C TIMP3 with
SpeI (Fig. 1, lanes 1 and 4), showed no cleavage of the PCR
product and thus confirmed the specificity of the RFLP
analysis.
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SFD patient fibroblasts
Having established that both S181C TIMP3 and E139X
TIMP3 cells produce mRNA from both mutant and wild-
type alleles, we went on to examine the forms of TIMP3
protein produced by immunoblotting. Because E139X
TIMP3 is C-terminally truncated, we used a polyclonal
antibody to the N terminus (first loop) of TIMP3. Initial
data showed that unstimulated fibroblasts produced very
low amounts of TIMP3 but the wild-type and monomeric
E139X TIMP3 were visible at low levels in cells/ECM
preparations after sample reduction (Fig. 2A, lane 3). We
therefore stimulated the expression of TIMP3 protein with
the translational enhancer CaPPs in combination with IL-1a
to facilitate detection [37]. Comparison of CaPPs/IL-1a
treated (Fig. 2A, lanes 2 and 4) and untreated (Fig. 2A,
lanes 1 and 3) samples for both S181C TIMP3 (Fig. 2A,
lanes 1 and 2) and E139X TIMP3 (Fig. 2A, lanes 3 and 4)
cells/ECM preparations demonstrated that this treatment 
 
Fig. 2. Analysis of expression and function of TIMP3 in SFD gingival fibroblas
carrying the S181C TIMP3 (lanes 1 and 2) mutation and a patient carrying the
untreated cells maintained in serum-free medium, lanes 2 and 4 are from cells whic
purified wild-type TIMP3 serves as a control (lane 5). (B) TIMP3 immunoblot o
carrying the S181C TIMP3 mutation as in panel A, non-reduced. (C) Reverse zym
treated with 10 ng/ml IL-1a plus 10 Ag/ml CaPPs. Standard consisted of purified
TIMP3; panel C, lane TIMP3).results in a stimulation of TIMP3 expression. Monomeric
S181C TIMP3 cannot be seen because it is indistinguishable
from wild-type TIMP3 on the basis of size in reduced gels.
Immunoblot analysis of S181C TIMP3 cells/ECM prepara-
tions (Fig. 2A, lanes 1 and 2) revealed bands corresponding
to glycosylated and non-glycosylated TIMP3 as well as a
cross-reactive band at 50 kDa. Non-reduced CaPPs/IL-1a-
treated S181C samples (Fig. 2B, lane 1) showed an addi-
tional band at approximately 46 kDa corresponding to
dimeric TIMP3 described by Langton et al. [15,31] and
Yeow et al. [32]. This demonstrated the presence of the
mutant S181C TIMP3 protein and its dimerisation in patient
fibroblasts, an observation also reported by Weber et al. [36]
in a study of dermal fibroblasts from a different S181C
TIMP3 pedigree. E139X TIMP3 is readily distinguishable
from wild-type TIMP3 on the basis of size (estimated Mr
16,000). The reduced CaPPs/IL-1a-treated E139X TIMP3
cells/ECM preparation (Fig. 2A, lane 4) clearly demonstra-
ted the presence of an additional TIMP3 reactive band of Mr
16,000. The relative intensities of the E139X TIMP3 andts. (A) TIMP3 immunoblot of reduced cells/ECM samples from a patient
E139X TIMP3 mutation (lanes 3 and 4). Lanes 1 and 3 are samples from
h have been stimulated with 10 ng/ml IL-1a plus 10 Ag/ml CaPPs. Partially
f the 10 ng/ml IL-1a plus 10 Ag/ml CaPPs-treated sample from a patient
ogram of cells/ECM from S181C (lane 1) and E139X (lane 2) patient cells
TIMP3 in both its glycosylated and non-glycosylated forms (panel A, lane
Fig. 3. Analysis of biochemical properties of recombinant E139X TIMP3
produced by HighFive lepidopteran cells. (A) TIMP3 immunoblot of wild-
type partially purified TIMP3 (lane 1) and recombinant E139X TIMP3
(lane 2) partially purified from conditioned medium from HighFive cells.
(B) Reverse zymograms of the same samples as in panel A.
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two alleles are equally expressed. Dimerisation of E139X
TIMP3 could not be assessed in SFD fibroblasts because
dimeric E139X TIMP3 runs at the same position as wild-
type glycosylated TIMP3 on polyacrylamide gels [31]. The
50-kDa cross-reactive band has also been observed by Yeow
et al. [32]. These authors reported that the 50-kDa band in
BHK cells transfected with mutant SFD-TIMP3 was of
greater intensity relative to TIMP3 than it was in BHK cells
transfected with wild-type TIMP3, and it was suggested that
this band represents an unidentified TIMP3 complex. We
consistently observe this band to be more abundant than the
wild-type TIMP3 band in SFD-TIMP3 gingival fibroblasts,
but it does not appear to have inhibitory activity against
MMP2 (Fig. 2C, lanes 1 and 2).
3.4. The activity of wild-type and SFD-TIMP3 protein in
patient fibroblasts
The issue of the MMP inhibitory activity of the mutant
TIMP3 proteins was addressed by reverse zymography,
using recombinant MMP2 as an in-gel MMP activity. Fig.
2C shows the reverse zymography profiles of S181C
TIMP3 and E139X TIMP3 cells/ECM extracts after treat-
ment with CaPPs/IL-1a. Patient cells showed a zone corre-
sponding to wild-type non-glycosylated TIMP3 and a much
more diffuse zone corresponding to glycosylated TIMP3
(Fig. 2C; arrows, lanes and 1 and 2). An inhibitory zone of
lower molecular weight than TIMP3 was also observed
which co-migrated with TIMP2 (results not shown).
S181C TIMP3 cells/ECM preparation displayed a band
unique to this sample corresponding to dimeric S181C
TIMP3 (Fig. 2C, lane 1). This confirms previous work
using recombinant systems [15,31,32]. No MMP2 inhibi-
tory activity was seen corresponding to the E139X TIMP3
monomer. Conclusions regarding the MMP-2 inhibitory
activity of the E139X dimer also could not be drawn from
this system because this protein runs on polyacrylamide gels
at the same position as wild-type glycosylated TIMP3 [31].
3.5. Biochemical properties of E139X TIMP3 expressed in
HighFive insect cells
Co-migration of the E139X dimer with the wild-type
glycosylated monomer made it difficult to study the inhib-
itory activity of the mutant dimer in patient fibroblasts. The
same problem arose when E139X TIMP3 was expressed as
a recombinant protein in COS-7 cells [31], since COS-7
cells endogenously produce wild-type TIMP3. To overcome
this problem, we expressed E139X TIMP3 as a recombinant
protein in HighFive insect cells which manufacture no
endogenous TIMP3 and do not produce an extensive
ECM. This allowed us to define the basic biochemical
properties of E139X TIMP3. Immunoblotting demonstrated
that E139X TIMP3 partially purified (see Materials and
methods) from the conditioned medium of HighFive cellswas present in both monomeric and dimeric forms (Fig. 3A,
lane 2), consistent with studies of S156C TIMP3 produced
by fibroblasts of mice homozygous for this allele [36].
Monomeric E139X TIMP3 predominated and dimeric
E139X TIMP3 ran at precisely the same position as glyco-
sylated wild-type TIMP3. The MMP-2 inhibitory activity of
E139X TIMP3 (Fig. 3B, lane 2) revealed a strong MMP-2
inhibitory zone corresponding to monomeric E139X
TIMP3. This demonstrated conclusively that the monomeric
E139X TIMP3 protein retains MMP2 inhibitory activity. An
inhibition zone was also observed in the region ofMr 27,000
which corresponds to dimeric E139X TIMP3.
3.6. Gelatinolytic profile of SFD gingival fibroblasts
It has recently been proposed that the effect of mutant
TIMP3, specifically S156C SFD-TIMP3, might be to
elevate the expression and activation of gelatinases by
SFD RPE cells, thereby stimulating subretinal angiogenesis
[33]. These conclusions were drawn from studies of trans-
fected ARPE-19 cell lines which express S156C SFD-
TIMP3 from a transfected gene under control of a cytome-
galovirus promoter. We therefore considered it to be of
interest to study gelatinase expression by patient cells
bearing a single copy of both mutant and wild-type TIMP3
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cells. The gelatinolytic profiles of S181C TIMP3 and
E139X TIMP3 gingival fibroblasts conditioned medium
(Fig. 4A, lanes 2 and 3) and cells/ECM preparations (Fig.
4A, lanes 5 and 6) showed no noticeable differences from
those of gingival fibroblasts from a non-SFD individual
(Fig. 4A, lanes 1 and 4). In all three cases, the conditioned
medium (Fig. 4A, lanes 1–3) displayed low amounts of
active MMP9, large amounts of pro-MMP2 and small
amounts of active MMP2. In all three cases, cells/ECM
preparations (Fig. 4A, lanes 4–6) showed no detectable
MMP9 activity, substantial amounts of proMMP2 activity
and barely detectable levels of active MMP2. A gelatino-
lytic activity smaller than active MMP2 was detected, but
not identified, in cells/ECM preparations (arrowed). An
unidentified higher molecular weight gelatinolytic activity
was detected in trace amounts in the conditioned medium
(Fig. 4A, lanes 1–3) and more substantial amounts in cells/Fig. 4. Comparison of the gelatinolytic profiles of gingival fibroblasts from a patie
individual. (A) Zymogram of gelatinase activity in the conditioned medium from g
from a non-SFD individual (lane 1) and in the corresponding cells/ECM samples (
DMEM (25 mM HEPES) containing 0.2% h-lactalbumin hydrolysate for 6 days b
conditioned medium which showed pro- and active MMP2 and MMP9 activity
conditioned medium from successive passages of E139X gingival fibroblasts in c
transferred into serum-free DMEM (25 mM HEPES) containing 0.2% h-lactalbum
ECM. Standard consisted of bovine nasal cartilage conditioned medium which sho
of gelatinase activity in the conditioned medium from gingival fibroblasts from S
from a non-SFD individual (lanes 1–3) treated for 24, 48 and 72 h with concentra
nasal cartilage conditioned medium which showed pro- and active MMP2 and MECM (Fig. 4A, lanes 4–6). The activity of this large
protease was not inhibited by 10 mM EDTA (data not
shown) and is not, therefore, considered to be a metal-
loprotease. Although the S156C TIMP3 mutant was not
studied, the results reported here indicate that expression of
mutant TIMP3 protein driven by the native TIMP3 pro-
moter does not necessarily give rise to increased expression
and activation of MMP2 and MMP9.
Gelatinase activity in the conditioned medium from
E139X TIMP3 gingival fibroblasts was further examined
with increasing passage number to study any potential
increase in MMP2 and MMP9 expression and activation
with time. Pro-MMP2 was consistently expressed at high
levels at all passages examined (Fig. 4B, lanes labelled
with passage number). Active MMP2 was observed at very
low levels at passages 9–12; at passage 13, however,
activation was slightly increased and remained at this level
for all the subsequent passages studied. A small amount ofnt carrying E139X TIMP3, a patient carrying S181C TIMP3 and a non-SFD
ingival fibroblasts from SFD patients (lanes 2 and 3) and gingival fibroblasts
lanes 4, 5 and 6). Confluent flasks of cells were transferred into serum-free
efore harvesting conditioned medium and cells/ECM. Bovine nasal cartilage
served as control (lane BNC). (B) Zymogram of gelatinase activity in the
ulture (lanes labelled with passage number). Confluent flasks of cells were
in hydrolysate for 6 days before harvesting conditioned medium and cells/
wed pro- and active MMP2 and MMP9 activity (lane BNC). (C) Zymogram
FD patients (E139X lanes 4–6; S181C lanes 7–9) and dermal fibroblasts
tions of Con A ranging from 0 to 100 Ag/ml. Standard consisted of bovine
MP9 activity (lane BNC).
C.E. Arris et al. / Biochimica et Biophysica Acta 1638 (2003) 20–28 27active MMP9 was detected at all passages examined. A
higher molecular weight gelatinolytic activity, which has
not yet been identified, was barely detectable at passages
9–11, but was present at much higher levels from passage
12.
The potential role of SFD-TIMP3, specifically S156C,
in the activation of pro-MMP2 has been addressed by
using Con A to induce membrane clustering of MT1-MMP
[33]. ARPE-19 retinal pigment epithelial cells transfected
with S156C TIMP3 were reported to show increased
expression and activation of MMP2 in response to Con
A treatment relative to ARPE-19 cells transfected with
wild-type TIMP3. MMP9 was present only in the condi-
tioned medium of cells expressing S156C TIMP3. It was
proposed that the mechanism of this increase in expression
and activation of MMP2 might be attenuated MMP2
inhibitory activity of mutant TIMP3 [33]. We studied the
effect of Con A on the gelatinolytic profile of the con-
ditioned medium from gingival fibroblasts from SFD
patients (Fig. 4C: E139X, lanes 4–6; S181C, lanes 7–8)
and dermal fibroblasts from a non-SFD individual (lanes
1–3) treated for 24, 48 and 72 h with concentrations of
Con A of 0, 50 and 100 Ag/ml or 0, 10 and 50 Ag/ml.
Untreated normal dermal and SFD gingival fibroblasts
expressed MMP2 almost entirely in the proform at all time
points. Con A treatment resulted in the activation of
MMP2 such that MMP2 was present almost entirely in
the active form at all time points and all concentrations of
Con A studied. Although MMP2 was activated by Con A
treatment, no increase in MMP2 expression was observed
in the three cell lines studied. MMP9 was unaffected by
Con A treatment. Thus, in contrast to data reported con-
cerning S156C-transfected ARPE-19 cells [33], we find
that mutant TIMP3 proteins, as studied in diploid fibro-
blasts, do not alter either the activation or expression levels
of MMP2 or MMP9.
This study confirms that mutant TIMP3 genes are tran-
scribed and translated to protein in fibroblast cells derived
from patients with SFD. This supports the general hypoth-
esis that mutant TIMP3 proteins cause SFD by a gain of
function mechanism possibly related to dimerisation or
oligomerisation of the mutant TIMP3 protein. Due to the
retention of MMP2 inhibitory activity by the mutated
TIMP3 proteins, this pathological gain of function is likely
to be unrelated to attenuated MMP inhibition. These results
are, however, in contrast to published work which specifi-
cally deals with the S156C TIMP3 SFD variant [33]. Our
results here with primary fibroblast cell lines derived from
two different SFD patients do not support the hypothesis
that increased synthesis and activation of MMP2 and MMP9
is a general facet of the possession of an SFD-TIMP3 allele.
Therefore, unless an S156C allele-specific or RPE cell-
specific mechanism is underlying the data of Qi et al.
[33], we feel that SFD pathology is also unlikely to be
specifically related to increased expression and activation of
MMP2 and MMP9.Acknowledgements
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